Crossmark

Durable disease control in unresectable hepatocellular carcinoma with atezolizumab plus half-dose bevacizumab: pathological complete response of peritoneal metastasis

Crossref DOI link: https://doi.org/10.1007/s12328-025-02265-1

Published Online: 2025-12-15

Published Print: 2026-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Mori, Haruki https://orcid.org/0000-0001-9143-256X
Maehira, Hiromitsu

Nitta, Nobuhito

Fujimoto, Shiori

Maekawa, Takeru

Miyake, Toru

Kaida, Sachiko

Takebayashi, Katsushi

Sonoda, Takeshi

Tani, Masaji
License Information

Text and Data Mining valid from 2025-12-15

Version of Record valid from 2025-12-15
More Information

Article History

Received: 24 October 2025

Accepted: 25 November 2025

First Online: 15 December 2025

Declarations

:

: The authors declare no conflicts of interest.

: Not applicable.

: Written informed consent was obtained from the patient for publication.

Document is current

Any future updates will be listed below